What is the P/E ratio of Zhejiang Huahai Pharmaceutical Co 2024?
The Zhejiang Huahai Pharmaceutical Co P/E ratio is 22.17.
Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news
Subscribe for $2 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news
Overview
Profile
Zhejiang Huahai Pharmaceutical Co stock price, quote, forecast and news stock price, forecast, news, chart, split, dividend and analysis Zhejiang Huahai Pharmaceutical Co ariva, Zhejiang Huahai Pharmaceutical Co onvista, Zhejiang Huahai Pharmaceutical Co finanzen.net, Zhejiang Huahai Pharmaceutical Co aktienfinder, Zhejiang Huahai Pharmaceutical Co marketscreener, Zhejiang Huahai Pharmaceutical Co marketwatch, Zhejiang Huahai Pharmaceutical Co bloomberg, Zhejiang Huahai Pharmaceutical Co handelsblatt, Zhejiang Huahai Pharmaceutical Co wiwo, Zhejiang Huahai Pharmaceutical Co forum
600521.SS
CNE000001DL5
Price
Price
18.00
Today +/-
+0.04
Today %
+1.68 %
Ticker600521.SS
ISINCNE000001DL5
P
Zhejiang Huahai Pharmaceutical Co stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Zhejiang Huahai Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Zhejiang Huahai Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Zhejiang Huahai Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Zhejiang Huahai Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Zhejiang Huahai Pharmaceutical Co Stock Price History
| Date | Zhejiang Huahai Pharmaceutical Co Price |
|---|---|
| 8/8/2024 | 18.00 undefined |
| 8/7/2024 | 17.70 undefined |
| 8/6/2024 | 17.82 undefined |
| 8/5/2024 | 17.54 undefined |
| 8/2/2024 | 17.52 undefined |
| 8/1/2024 | 17.26 undefined |
| 7/31/2024 | 17.15 undefined |
| 7/30/2024 | 16.10 undefined |
| 7/29/2024 | 16.24 undefined |
| 7/26/2024 | 16.64 undefined |
| 7/25/2024 | 16.60 undefined |
| 7/24/2024 | 16.69 undefined |
| 7/23/2024 | 16.93 undefined |
| 7/22/2024 | 17.71 undefined |
| 7/19/2024 | 17.38 undefined |
| 7/18/2024 | 17.68 undefined |
| 7/17/2024 | 17.54 undefined |
| 7/16/2024 | 17.46 undefined |
| 7/15/2024 | 17.45 undefined |
| 7/12/2024 | 17.79 undefined |
| 7/11/2024 | 17.80 undefined |
| 7/10/2024 | 17.79 undefined |
Zhejiang Huahai Pharmaceutical Co Revenue, EBIT, Net Income CNE000001DL5 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Zhejiang Huahai Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zhejiang Huahai Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zhejiang Huahai Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Zhejiang Huahai Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Zhejiang Huahai Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Zhejiang Huahai Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zhejiang Huahai Pharmaceutical Co’s growth potential.
Zhejiang Huahai Pharmaceutical Co Revenue, EBIT and net profit per share
| Date | Zhejiang Huahai Pharmaceutical Co Revenue | Zhejiang Huahai Pharmaceutical Co EBIT | Zhejiang Huahai Pharmaceutical Co Net Income |
|---|---|---|---|
| 2026e | 12.06 B undefined | 2.3 B undefined | 1.55 B undefined |
| 2025e | 11.35 B undefined | 2.09 B undefined | 1.39 B undefined |
| 2024e | 9.97 B undefined | 1.89 B undefined | 1.18 B undefined |
| 2023 | 8.31 B undefined | 1.45 B undefined | 830.47 M undefined |
| 2022 | 8.27 B undefined | 1.6 B undefined | 1.17 B undefined |
| 2021 | 6.64 B undefined | 604.86 M undefined | 487.54 M undefined |
| 2020 | 6.49 B undefined | 1.5 B undefined | 929.8 M undefined |
| 2019 | 5.39 B undefined | 1.02 B undefined | 569.6 M undefined |
| 2018 | 5.09 B undefined | 656.3 M undefined | 107.5 M undefined |
| 2017 | 5 B undefined | 895.2 M undefined | 639.2 M undefined |
| 2016 | 4.09 B undefined | 490.5 M undefined | 500.8 M undefined |
| 2015 | 3.5 B undefined | 479.7 M undefined | 442.5 M undefined |
| 2014 | 2.59 B undefined | 324 M undefined | 265.5 M undefined |
| 2013 | 2.3 B undefined | 401.1 M undefined | 359.2 M undefined |
| 2012 | 2.01 B undefined | 377.6 M undefined | 341.1 M undefined |
| 2011 | 1.83 B undefined | 325.9 M undefined | 216.9 M undefined |
| 2010 | 1.02 B undefined | 110.5 M undefined | 93.6 M undefined |
| 2009 | 928 M undefined | 184 M undefined | 165 M undefined |
| 2008 | 801.4 M undefined | 193.8 M undefined | 150.1 M undefined |
| 2007 | 707 M undefined | 202.2 M undefined | 132 M undefined |
| 2006 | 560.1 M undefined | 150.3 M undefined | 110.7 M undefined |
| 2005 | 423.2 M undefined | 163 M undefined | 128.9 M undefined |
| 2004 | 391.1 M undefined | 146.5 M undefined | 119.1 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 391.1 M CNY | 146.5 M CNY | 119.1 M CNY |
| 2005 | 423.2 M CNY | 163 M CNY | 128.9 M CNY |
| 2006 | 560.1 M CNY | 150.3 M CNY | 110.7 M CNY |
| 2007 | 707 M CNY | 202.2 M CNY | 132 M CNY |
| 2008 | 801.4 M CNY | 193.8 M CNY | 150.1 M CNY |
| 2009 | 928 M CNY | 184 M CNY | 165 M CNY |
| 2010 | 1.02 B CNY | 110.5 M CNY | 93.6 M CNY |
| 2011 | 1.83 B CNY | 325.9 M CNY | 216.9 M CNY |
| 2012 | 2.01 B CNY | 377.6 M CNY | 341.1 M CNY |
| 2013 | 2.3 B CNY | 401.1 M CNY | 359.2 M CNY |
| 2014 | 2.59 B CNY | 324 M CNY | 265.5 M CNY |
| 2015 | 3.5 B CNY | 479.7 M CNY | 442.5 M CNY |
| 2016 | 4.09 B CNY | 490.5 M CNY | 500.8 M CNY |
| 2017 | 5 B CNY | 895.2 M CNY | 639.2 M CNY |
| 2018 | 5.09 B CNY | 656.3 M CNY | 107.5 M CNY |
| 2019 | 5.39 B CNY | 1.02 B CNY | 569.6 M CNY |
| 2020 | 6.49 B CNY | 1.5 B CNY | 929.8 M CNY |
| 2021 | 6.64 B CNY | 604.86 M CNY | 487.54 M CNY |
| 2022 | 8.27 B CNY | 1.6 B CNY | 1.17 B CNY |
| 2023 | 8.31 B CNY | 1.45 B CNY | 830.47 M CNY |
| 2024e | 9.97 B CNY | 1.89 B CNY | 1.18 B CNY |
| 2025e | 11.35 B CNY | 2.09 B CNY | 1.39 B CNY |
| 2026e | 12.06 B CNY | 2.3 B CNY | 1.55 B CNY |
Zhejiang Huahai Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.14 | 0.18 | 0.19 | 0.3 | 0.39 | 0.42 | 0.56 | 0.71 | 0.8 | 0.93 | 1.02 | 1.83 | 2.01 | 2.3 | 2.59 | 3.5 | 4.09 | 5 | 5.09 | 5.39 | 6.49 | 6.64 | 8.27 | 8.31 | 9.97 | 11.35 | 12.06 |
| - | 30.15 | 5.65 | 62.03 | 29.04 | 8.18 | 32.39 | 26.25 | 13.30 | 15.86 | 10.13 | 78.77 | 10.24 | 14.00 | 12.59 | 35.40 | 16.91 | 22.24 | 1.84 | 5.77 | 20.36 | 2.44 | 24.42 | 0.52 | 19.97 | 13.84 | 6.29 |
| 50.74 | 42.37 | 53.48 | 52.81 | 49.87 | 54.37 | 47.68 | 45.83 | 45.57 | 40.73 | 41.19 | 37.82 | 40.12 | 43.55 | 44.49 | 48.49 | 49.88 | 55.96 | 57.99 | 59.11 | 63.22 | 59.51 | 61.43 | 59.21 | - | - | - |
| 0.07 | 0.08 | 0.1 | 0.16 | 0.2 | 0.23 | 0.27 | 0.32 | 0.37 | 0.38 | 0.42 | 0.69 | 0.81 | 1 | 1.15 | 1.7 | 2.04 | 2.8 | 2.95 | 3.19 | 4.1 | 3.95 | 5.08 | 4.92 | 0 | 0 | 0 |
| 0.05 | 0.05 | 0.08 | 0.12 | 0.15 | 0.16 | 0.15 | 0.2 | 0.19 | 0.18 | 0.11 | 0.33 | 0.38 | 0.4 | 0.32 | 0.48 | 0.49 | 0.9 | 0.66 | 1.02 | 1.5 | 0.6 | 1.6 | 1.45 | 1.89 | 2.09 | 2.3 |
| 38.97 | 29.94 | 40.11 | 39.93 | 37.34 | 38.53 | 26.79 | 28.57 | 24.09 | 19.83 | 10.76 | 17.79 | 18.72 | 17.47 | 12.53 | 13.69 | 11.97 | 17.89 | 12.88 | 18.97 | 23.16 | 9.09 | 19.36 | 17.43 | 18.91 | 18.38 | 19.05 |
| 0.03 | 0.04 | 0.05 | 0.08 | 0.12 | 0.13 | 0.11 | 0.13 | 0.15 | 0.17 | 0.09 | 0.22 | 0.34 | 0.36 | 0.27 | 0.44 | 0.5 | 0.64 | 0.11 | 0.57 | 0.93 | 0.49 | 1.17 | 0.83 | 1.18 | 1.39 | 1.55 |
| - | 23.53 | 19.05 | 58.00 | 50.63 | 7.56 | -14.06 | 20.00 | 13.64 | 10.00 | -43.64 | 132.26 | 57.87 | 5.28 | -26.18 | 66.79 | 13.12 | 27.80 | -83.26 | 431.78 | 63.27 | -47.58 | 139.63 | -28.88 | 42.41 | 17.51 | 11.59 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 0.79 | 0.79 | 0.79 | 1.22 | 1.22 | 1.22 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.22 | 1.28 | 1.35 | 1.35 | 1.35 | 1.37 | 1.38 | 1.39 | 1.45 | 1.43 | 1.46 | 1.46 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Zhejiang Huahai Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Zhejiang Huahai Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Zhejiang Huahai Pharmaceutical Co stock margins CNE000001DL5 ·
The Zhejiang Huahai Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zhejiang Huahai Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zhejiang Huahai Pharmaceutical Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Zhejiang Huahai Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Zhejiang Huahai Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Zhejiang Huahai Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Zhejiang Huahai Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zhejiang Huahai Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zhejiang Huahai Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zhejiang Huahai Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Zhejiang Huahai Pharmaceutical Co Margin History
| Zhejiang Huahai Pharmaceutical Co Gross margin | Zhejiang Huahai Pharmaceutical Co Profit margin | Zhejiang Huahai Pharmaceutical Co EBIT margin | Zhejiang Huahai Pharmaceutical Co Profit margin |
|---|---|---|---|
| 2026e | 59.21 % | 19.05 % | 12.86 % |
| 2025e | 59.21 % | 18.38 % | 12.25 % |
| 2024e | 59.21 % | 18.91 % | 11.87 % |
| 2023 | 59.21 % | 17.43 % | 10 % |
| 2022 | 61.43 % | 19.37 % | 14.13 % |
| 2021 | 59.51 % | 9.1 % | 7.34 % |
| 2020 | 63.23 % | 23.17 % | 14.34 % |
| 2019 | 59.11 % | 18.97 % | 10.57 % |
| 2018 | 57.99 % | 12.88 % | 2.11 % |
| 2017 | 55.96 % | 17.9 % | 12.78 % |
| 2016 | 49.88 % | 11.98 % | 12.24 % |
| 2015 | 48.51 % | 13.7 % | 12.64 % |
| 2014 | 44.5 % | 12.53 % | 10.27 % |
| 2013 | 43.59 % | 17.47 % | 15.64 % |
| 2012 | 40.13 % | 18.75 % | 16.93 % |
| 2011 | 37.82 % | 17.83 % | 11.87 % |
| 2010 | 41.24 % | 10.8 % | 9.15 % |
| 2009 | 40.77 % | 19.83 % | 17.78 % |
| 2008 | 45.61 % | 24.18 % | 18.73 % |
| 2007 | 45.84 % | 28.6 % | 18.67 % |
| 2006 | 47.71 % | 26.83 % | 19.76 % |
| 2005 | 54.4 % | 38.52 % | 30.46 % |
| 2004 | 49.94 % | 37.46 % | 30.45 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 49.94 % | 37.46 % | 30.45 % |
| 2005 | 54.4 % | 38.52 % | 30.46 % |
| 2006 | 47.71 % | 26.83 % | 19.76 % |
| 2007 | 45.84 % | 28.6 % | 18.67 % |
| 2008 | 45.61 % | 24.18 % | 18.73 % |
| 2009 | 40.77 % | 19.83 % | 17.78 % |
| 2010 | 41.24 % | 10.8 % | 9.15 % |
| 2011 | 37.82 % | 17.83 % | 11.87 % |
| 2012 | 40.13 % | 18.75 % | 16.93 % |
| 2013 | 43.59 % | 17.47 % | 15.64 % |
| 2014 | 44.5 % | 12.53 % | 10.27 % |
| 2015 | 48.51 % | 13.7 % | 12.64 % |
| 2016 | 49.88 % | 11.98 % | 12.24 % |
| 2017 | 55.96 % | 17.9 % | 12.78 % |
| 2018 | 57.99 % | 12.88 % | 2.11 % |
| 2019 | 59.11 % | 18.97 % | 10.57 % |
| 2020 | 63.23 % | 23.17 % | 14.34 % |
| 2021 | 59.51 % | 9.1 % | 7.34 % |
| 2022 | 61.43 % | 19.37 % | 14.13 % |
| 2023 | 59.21 % | 17.43 % | 10 % |
| 2024e | 59.21 % | 18.91 % | 11.87 % |
| 2025e | 59.21 % | 18.38 % | 12.25 % |
| 2026e | 59.21 % | 19.05 % | 12.86 % |
Zhejiang Huahai Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share CNE000001DL5 ·
The Zhejiang Huahai Pharmaceutical Co earnings per share therefore indicates how much revenue Zhejiang Huahai Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Zhejiang Huahai Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Zhejiang Huahai Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Zhejiang Huahai Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zhejiang Huahai Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Zhejiang Huahai Pharmaceutical Co Revenue, EBIT and net profit per share
| Date | Zhejiang Huahai Pharmaceutical Co Sales per Share | Zhejiang Huahai Pharmaceutical Co EBIT per share | Zhejiang Huahai Pharmaceutical Co Earnings per Share |
|---|---|---|---|
| 2026e | 8.44 undefined | 0 undefined | 1.09 undefined |
| 2025e | 7.94 undefined | 0 undefined | 0.97 undefined |
| 2024e | 6.98 undefined | 0 undefined | 0.83 undefined |
| 2023 | 5.7 undefined | 0.99 undefined | 0.57 undefined |
| 2022 | 5.66 undefined | 1.1 undefined | 0.8 undefined |
| 2021 | 4.63 undefined | 0.42 undefined | 0.34 undefined |
| 2020 | 4.46 undefined | 1.03 undefined | 0.64 undefined |
| 2019 | 3.87 undefined | 0.73 undefined | 0.41 undefined |
| 2018 | 3.7 undefined | 0.48 undefined | 0.08 undefined |
| 2017 | 3.65 undefined | 0.65 undefined | 0.47 undefined |
| 2016 | 3.03 undefined | 0.36 undefined | 0.37 undefined |
| 2015 | 2.6 undefined | 0.36 undefined | 0.33 undefined |
| 2014 | 1.92 undefined | 0.24 undefined | 0.2 undefined |
| 2013 | 1.79 undefined | 0.31 undefined | 0.28 undefined |
| 2012 | 1.65 undefined | 0.31 undefined | 0.28 undefined |
| 2011 | 1.52 undefined | 0.27 undefined | 0.18 undefined |
| 2010 | 0.85 undefined | 0.09 undefined | 0.08 undefined |
| 2009 | 0.77 undefined | 0.15 undefined | 0.14 undefined |
| 2008 | 0.67 undefined | 0.16 undefined | 0.12 undefined |
| 2007 | 0.59 undefined | 0.17 undefined | 0.11 undefined |
| 2006 | 0.47 undefined | 0.13 undefined | 0.09 undefined |
| 2005 | 0.35 undefined | 0.13 undefined | 0.11 undefined |
| 2004 | 0.32 undefined | 0.12 undefined | 0.1 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2004 | 0.32 CNY | 0.12 CNY | 0.1 CNY |
| 2005 | 0.35 CNY | 0.13 CNY | 0.11 CNY |
| 2006 | 0.47 CNY | 0.13 CNY | 0.09 CNY |
| 2007 | 0.59 CNY | 0.17 CNY | 0.11 CNY |
| 2008 | 0.67 CNY | 0.16 CNY | 0.12 CNY |
| 2009 | 0.77 CNY | 0.15 CNY | 0.14 CNY |
| 2010 | 0.85 CNY | 0.09 CNY | 0.08 CNY |
| 2011 | 1.52 CNY | 0.27 CNY | 0.18 CNY |
| 2012 | 1.65 CNY | 0.31 CNY | 0.28 CNY |
| 2013 | 1.79 CNY | 0.31 CNY | 0.28 CNY |
| 2014 | 1.92 CNY | 0.24 CNY | 0.2 CNY |
| 2015 | 2.6 CNY | 0.36 CNY | 0.33 CNY |
| 2016 | 3.03 CNY | 0.36 CNY | 0.37 CNY |
| 2017 | 3.65 CNY | 0.65 CNY | 0.47 CNY |
| 2018 | 3.7 CNY | 0.48 CNY | 0.08 CNY |
| 2019 | 3.87 CNY | 0.73 CNY | 0.41 CNY |
| 2020 | 4.46 CNY | 1.03 CNY | 0.64 CNY |
| 2021 | 4.63 CNY | 0.42 CNY | 0.34 CNY |
| 2022 | 5.66 CNY | 1.1 CNY | 0.8 CNY |
| 2023 | 5.7 CNY | 0.99 CNY | 0.57 CNY |
| 2024e | 6.98 CNY | 0 CNY | 0.83 CNY |
| 2025e | 7.94 CNY | 0 CNY | 0.97 CNY |
| 2026e | 8.44 CNY | 0 CNY | 1.09 CNY |
Zhejiang Huahai Pharmaceutical Co business model
Zhejiang Huahai Pharmaceutical Co is one of the most popular companies on Eulerpool.com.
Zhejiang Huahai Pharmaceutical Co Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Zhejiang Huahai Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.
Zhejiang Huahai Pharmaceutical Co shares outstanding CNE000001DL5 ·
The number of shares was Zhejiang Huahai Pharmaceutical Co in 2023 — This indicates how many shares 1.457 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Zhejiang Huahai Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Zhejiang Huahai Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Zhejiang Huahai Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zhejiang Huahai Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 1.22 B Aktien |
| 2005 | 1.22 B Aktien |
| 2006 | 1.2 B Aktien |
| 2007 | 1.2 B Aktien |
| 2008 | 1.2 B Aktien |
| 2009 | 1.2 B Aktien |
| 2010 | 1.2 B Aktien |
| 2011 | 1.2 B Aktien |
| 2012 | 1.22 B Aktien |
| 2013 | 1.28 B Aktien |
| 2014 | 1.35 B Aktien |
| 2015 | 1.35 B Aktien |
| 2016 | 1.35 B Aktien |
| 2017 | 1.37 B Aktien |
| 2018 | 1.38 B Aktien |
| 2019 | 1.39 B Aktien |
| 2020 | 1.45 B Aktien |
| 2021 | 1.43 B Aktien |
| 2022 | 1.46 B Aktien |
| 2023 | 1.46 B Aktien |
| 2024e | 1.46 B Aktien |
| 2025e | 1.46 B Aktien |
| 2026e | 1.46 B Aktien |
Zhejiang Huahai Pharmaceutical Co Stock splits
In Zhejiang Huahai Pharmaceutical Co's history, there have been no stock splits.
Zhejiang Huahai Pharmaceutical Co dividend history and estimates CNE000001DL5 ·
In 2023, Zhejiang Huahai Pharmaceutical Co paid a dividend amounting to 0.24 CNY. Dividend means that Zhejiang Huahai Pharmaceutical Co distributes a portion of its profits to its owners.
3 years
5 years
10 years
25 Years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for Zhejiang Huahai Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Zhejiang Huahai Pharmaceutical Co’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating Zhejiang Huahai Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Zhejiang Huahai Pharmaceutical Co Dividend History
| Date | Zhejiang Huahai Pharmaceutical Co Dividend |
|---|---|
| 2026e | 0.27 undefined |
| 2025e | 0.27 undefined |
| 2024e | 0.26 undefined |
| 2023 | 0.24 undefined |
| 2022 | 0.1 undefined |
| 2021 | 0.2 undefined |
| 2020 | 0.18 undefined |
| 2018 | 0.15 undefined |
| 2017 | 0.14 undefined |
| 2016 | 0.12 undefined |
| 2015 | 0.09 undefined |
| 2014 | 0.12 undefined |
| 2013 | 0.09 undefined |
| 2012 | 0.04 undefined |
| 2011 | 0.04 undefined |
| 2010 | 0.02 undefined |
| 2009 | 0.05 undefined |
| 2008 | 0.02 undefined |
| 2007 | 0.04 undefined |
| 2005 | 0.11 undefined |
| 2004 | 0.03 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2004 | 0.03 CNY | 0 CNY |
| 2005 | 0.11 CNY | 0 CNY |
| 2006 | 0 CNY | 0 CNY |
| 2007 | 0.04 CNY | 0 CNY |
| 2008 | 0.02 CNY | 0 CNY |
| 2009 | 0.05 CNY | 0 CNY |
| 2010 | 0.02 CNY | 0 CNY |
| 2011 | 0.04 CNY | 0 CNY |
| 2012 | 0.04 CNY | 0 CNY |
| 2013 | 0.09 CNY | 0 CNY |
| 2014 | 0.12 CNY | 0 CNY |
| 2015 | 0.09 CNY | 0 CNY |
| 2016 | 0.12 CNY | 0 CNY |
| 2017 | 0.14 CNY | 0 CNY |
| 2018 | 0.15 CNY | 0 CNY |
| 2019 | 0 CNY | 0 CNY |
| 2020 | 0.18 CNY | 0 CNY |
| 2021 | 0.2 CNY | 0 CNY |
| 2022 | 0.1 CNY | 0 CNY |
| 2023 | 0.24 CNY | 0 CNY |
| 2024e | 0 CNY | 0.26 CNY |
| 2025e | 0 CNY | 0.27 CNY |
| 2026e | 0 CNY | 0.27 CNY |
Zhejiang Huahai Pharmaceutical Co dividend payout ratio CNE000001DL5 ·
In 2023, Zhejiang Huahai Pharmaceutical Co had a payout ratio of 33.24%. The payout ratio indicates the percentage of the company's profits that Zhejiang Huahai Pharmaceutical Co distributes as dividends.
3 years
5 years
10 years
25 Years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for Zhejiang Huahai Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for Zhejiang Huahai Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate Zhejiang Huahai Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Zhejiang Huahai Pharmaceutical Co Payout Ratio History
| Date | Zhejiang Huahai Pharmaceutical Co Payout ratio |
|---|---|
| 2026e | 31.66 % |
| 2025e | 26.87 % |
| 2024e | 34.86 % |
| 2023 | 33.24 % |
| 2022 | 12.5 % |
| 2021 | 58.82 % |
| 2020 | 28.41 % |
| 2019 | 33.24 % |
| 2018 | 189.38 % |
| 2017 | 29.02 % |
| 2016 | 31.51 % |
| 2015 | 26.48 % |
| 2014 | 58.3 % |
| 2013 | 32.04 % |
| 2012 | 16 % |
| 2011 | 20.78 % |
| 2010 | 31.13 % |
| 2009 | 35.57 % |
| 2008 | 16 % |
| 2007 | 34.82 % |
| 2006 | 33.24 % |
| 2005 | 95.82 % |
| 2004 | 29.5 % |
| Payout ratio | |
|---|---|
| 2004 | 29.5 % |
| 2005 | 95.82 % |
| 2006 | 33.24 % |
| 2007 | 34.82 % |
| 2008 | 16 % |
| 2009 | 35.57 % |
| 2010 | 31.13 % |
| 2011 | 20.78 % |
| 2012 | 16 % |
| 2013 | 32.04 % |
| 2014 | 58.3 % |
| 2015 | 26.48 % |
| 2016 | 31.51 % |
| 2017 | 29.02 % |
| 2018 | 189.38 % |
| 2019 | 33.24 % |
| 2020 | 28.41 % |
| 2021 | 58.82 % |
| 2022 | 12.5 % |
| 2023 | 33.24 % |
| 2024e | 34.86 % |
| 2025e | 26.87 % |
| 2026e | 31.66 % |
Unfortunately, there are currently no price targets and forecasts available for Zhejiang Huahai Pharmaceutical Co.
Zhejiang Huahai Pharmaceutical Co latest earnings and earnings surprises
| Date | EPS Estimate | EPS Actual | Quarterly report |
|---|---|---|---|
| 3/31/2024 | 0.2 | 0.19 (-3.55 %) | 2024 Q1 |
| 12/31/2023 | 0.19 | 0.07 (-63.52 %) | 2023 Q4 |
| 9/30/2023 | 0.21 | 0.11 (-48.14 %) | 2023 Q3 |
| 6/30/2023 | 0.23 | 0.27 (16.23 %) | 2023 Q2 |
| 3/31/2023 | 0.17 | 0.12 (-30.11 %) | 2023 Q1 |
| 12/31/2022 | 0.13 | 0.26 (98.02 %) | 2022 Q4 |
| 9/30/2022 | 0.22 | 0.16 (-27.99 %) | 2022 Q3 |
| 6/30/2022 | 0.19 | 0.29 (51.12 %) | 2022 Q2 |
| 3/31/2022 | 0.14 | 0.09 (-33.68 %) | 2022 Q1 |
| 12/31/2021 | 0.17 | -0.08 (-146.59 %) | 2021 Q4 |
1
2
3
4
5
...
6
Eulerpool ESG Scorecard© for the Zhejiang Huahai Pharmaceutical Co stock
Eulerpool World ESG Rating (EESG©)
63/ 100
🌱 Environment
68
👫 Social
87
🏛️ Governance
34
Environment
Scope 1 - Direct Emissions | — |
Scope 2 - Indirect emissions from purchased energy | — |
Scope 3 - Indirect emissions within the value chain | — |
Total CO₂ emissions | 291,642.91 |
| CO₂ reduction strategy | ✅ |
| Coal energy | ❌ |
| Nuclear power | ❌ |
| Animal experiments | ✅ |
| Fur & Leather | — |
| Pesticides | — |
| Palm Oil | — |
| Tobacco | ❌ |
| Genetically modified organisms | ❌ |
| Climate concept | — |
| Sustainable forestry | — |
| Recycling regulations | ❌ |
| Environmentally friendly packaging | ❌ |
| Hazardous substances | ❌ |
| Fuel consumption and efficiency | ❌ |
| Water consumption and efficiency | ✅ |
Social
| Percentage of female employees | 42.2 |
| Percentage of women in management | — |
| Percentage of Asian employees | — |
| Share of Asian management | — |
| Percentage of Hispanic/Latino employees | — |
| Hispano/Latino Management share | — |
| Percentage of Black employees | — |
| Black Management Share | — |
| Percentage of white employees | — |
| White Management Share | — |
| Adult content | ❌ |
| Alcohol | ❌ |
| Weapons | — |
| Firearms | ❌ |
| Gambling | ❌ |
| Military contracts | ❌ |
| Human rights concept | ✅ |
| Privacy concept | — |
| Occupational health and safety | ✅ |
| Catholic | ✅ |
Governance (Corporate Governance)
| Environmental reporting | ✅ |
| Stakeholder Engagement | ✅ |
| Call Back Policies | ❌ |
| Antitrust law | ❌ |
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Zhejiang Huahai Pharmaceutical Co list of shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 25.61 % | Chen (Baohua) | 365,697,935 | 0 | 9/30/2023 |
| 15.71 % | Zhou (Minghua) | 224,418,890 | 0 | 9/30/2023 |
| 0.97 % | China Merchants Fund Management Co. Ltd. | 13,923,743 | -2,101,356 | 12/31/2023 |
| 0.87 % | Taizhou Financial Investment Group Co Ltd | 12,462,871 | 0 | 9/30/2023 |
| 0.71 % | Essence Fund Management Co., Ltd. | 10,109,784 | -742,286 | 9/30/2023 |
| 0.64 % | Linhai Financial Investment Co., Ltd. | 9,145,526 | 0 | 9/30/2023 |
| 0.62 % | Taikang Asset Management Co., Ltd. | 8,917,990 | -100 | 12/31/2023 |
| 0.62 % | Su (Chunlian) | 8,793,379 | 0 | 9/30/2023 |
| 0.61 % | Harvest Fund Management Co., Ltd. | 8,734,435 | -794,800 | 9/30/2023 |
| 0.60 % | Guotai Asset Management Co., Ltd. | 8,500,847 | -9,644,405 | 9/30/2023 |
1
2
3
4
5
...
10
Zhejiang Huahai Pharmaceutical Co Executives and Management Board
Mr. Bin He47
Zhejiang Huahai Pharmaceutical Co Vice President
Compensation 3.14 M
Mr. Hong Li62
Zhejiang Huahai Pharmaceutical Co Chairman of the Board (since 2019)
Compensation 3.12 M
Ms. Hui Gang41
Zhejiang Huahai Pharmaceutical Co Vice President
Compensation 2.48 M
Mr. Baohua Chen61
Zhejiang Huahai Pharmaceutical Co President, Director (since 2019)
Compensation 2.01 M
Mr. Sijia Guo60
Zhejiang Huahai Pharmaceutical Co Executive Vice President, Director
Compensation 1.97 M
1
2
3
4
Zhejiang Huahai Pharmaceutical Co Supply Chain
| Name | Relationship | Two-week correlation | One-month correlation | Three-Month Correlation | Six-Month Correlation | One Year Correlation | Two-Year Correlation |
|---|---|---|---|---|---|---|---|
| SupplierCustomer | 1,00 | 0,97 | 0,91 | 0,53 | 0,55 | -0,04 | |
| SupplierCustomer | 0,98 | 0,86 | 0,73 | 0,48 | 0,14 | -0,63 | |
| SupplierCustomer | 0,96 | 0,97 | 0,92 | 0,70 | 0,15 | 0,16 | |
 Forest Packaging Group A | SupplierCustomer | 0,68 | 0,69 | 0,51 | 0,40 | 0,15 | - |
| SupplierCustomer | 0,64 | 0,83 | 0,18 | 0,05 | -0,46 | -0,81 | |
| SupplierCustomer | 0,45 | 0,79 | 0,45 | 0,16 | -0,23 | -0,68 | |
| SupplierCustomer | -0,44 | 0,66 | 0,86 | 0,27 | -0,06 | 0,57 |
1
Most common questions regarding Zhejiang Huahai Pharmaceutical Co
What is the P/S ratio of Zhejiang Huahai Pharmaceutical Co 2024?
The Zhejiang Huahai Pharmaceutical Co P/S ratio is 2.63.
What is the AlleAktien quality score of Zhejiang Huahai Pharmaceutical Co?
The AlleAktien quality score for Zhejiang Huahai Pharmaceutical Co is 5/10.
What is the revenue of Zhejiang Huahai Pharmaceutical Co 2024?
The expected Zhejiang Huahai Pharmaceutical Co revenue is 9.97 B CNY.
How high is the profit of Zhejiang Huahai Pharmaceutical Co 2024?
The expected Zhejiang Huahai Pharmaceutical Co profit is 1.18 B CNY.
What is the business model of Zhejiang Huahai Pharmaceutical Co
No history available for Zhejiang Huahai Pharmaceutical Co.
What is the Zhejiang Huahai Pharmaceutical Co dividend?
Zhejiang Huahai Pharmaceutical Co pays a dividend of 0.1 CNY distributed over payouts per year.
How often does Zhejiang Huahai Pharmaceutical Co pay dividends?
The dividend cannot currently be calculated for Zhejiang Huahai Pharmaceutical Co or the company does not pay out a dividend.
What is the Zhejiang Huahai Pharmaceutical Co ISIN?
The ISIN of Zhejiang Huahai Pharmaceutical Co is CNE000001DL5.
What is the Zhejiang Huahai Pharmaceutical Co ticker?
The ticker of Zhejiang Huahai Pharmaceutical Co is 600521.SS.
How much dividend does Zhejiang Huahai Pharmaceutical Co pay?
Over the past 12 months, Zhejiang Huahai Pharmaceutical Co paid a dividend of 0.24 CNY . This corresponds to a dividend yield of about 1.33 %. For the coming 12 months, Zhejiang Huahai Pharmaceutical Co is expected to pay a dividend of 0.27 CNY.
What is the dividend yield of Zhejiang Huahai Pharmaceutical Co?
The current dividend yield of Zhejiang Huahai Pharmaceutical Co is 1.33 %.
When does Zhejiang Huahai Pharmaceutical Co pay dividends?
Zhejiang Huahai Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, August, August, August.
How secure is the dividend of Zhejiang Huahai Pharmaceutical Co?
Zhejiang Huahai Pharmaceutical Co paid dividends every year for the past 7 years.
What is the dividend of Zhejiang Huahai Pharmaceutical Co?
For the upcoming 12 months, dividends amounting to 0.27 CNY are expected. This corresponds to a dividend yield of 1.48 %.
In which sector is Zhejiang Huahai Pharmaceutical Co located?
Zhejiang Huahai Pharmaceutical Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zhejiang Huahai Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zhejiang Huahai Pharmaceutical Co from 7/10/2024 amounting to 0.2 CNY, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.
When did Zhejiang Huahai Pharmaceutical Co pay the last dividend?
The last dividend was paid out on 7/10/2024.
What was the dividend of Zhejiang Huahai Pharmaceutical Co in the year 2023?
In the year 2023, Zhejiang Huahai Pharmaceutical Co distributed 0.1 CNY as dividends.
In which currency does Zhejiang Huahai Pharmaceutical Co pay out the dividend?
The dividends of Zhejiang Huahai Pharmaceutical Co are distributed in CNY.
Zhejiang Huahai Pharmaceutical Co stock price, news, forecast, analysis
Sector
Health
Industry
Pharmaceuticals
Number of shares
Employee
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
People's Republic of China 🇨🇳
Currency
CNY
Initial public offering
Mar 4, 2003
GOSIN
Global Open Securities Identification Number
Cusip
Y9891X103
Market capitalization
PEG
3.34
P/E
Forward P/E
21.73
P/S
Forward P/S
2.31
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC
4.47 %
Dividend
Dividend yield
1.33 %
Dividend growth Ø5Y
—
Dividends per year
Paid since
4 years
Not cut since
1 year
Increased since
1 year
Dividends tax
25.83 %
Scalable Capital savings plan Nein
Trade Republic savings plan Nein
comdirect savings plan
Consorsbank savings plan Nein
ING savings plan Nein
Zhejiang Huahai Pharmaceutical Co Peer Group
Zhejiang Huahai Pharmaceutical Co Eulerpool News
Zhejiang Huahai Pharmaceutical Co News
Zhejiang Huahai Pharmaceutical Co Ticker
| Stock Exchange | Zhejiang Huahai Pharmaceutical Co Ticker |
|---|---|
| SHH | 600521.SS |
Zhejiang Huahai Pharmaceutical Co FIGI
| Zhejiang Huahai Pharmaceutical Co Ticker | Zhejiang Huahai Pharmaceutical Co FIGI |
|---|---|
| 600521:CH | BBG000PPKRW9 |
| 600521:CG | BBG000PPKSG5 |
| 600521:C1 | BBG00709HTS2 |
All fundamentals about Zhejiang Huahai Pharmaceutical Co
Our stock analysis for Zhejiang Huahai Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zhejiang Huahai Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Zhejiang Huahai Pharmaceutical Co Revenue
- Zhejiang Huahai Pharmaceutical Co Net Income
- Zhejiang Huahai Pharmaceutical Co P/E
- Zhejiang Huahai Pharmaceutical Co P/S
- Zhejiang Huahai Pharmaceutical Co EBIT
- Zhejiang Huahai Pharmaceutical Co Dividend
- Zhejiang Huahai Pharmaceutical Co Stocks
- Zhejiang Huahai Pharmaceutical Co Market capitalization
- Zhejiang Huahai Pharmaceutical Co Debt
- Zhejiang Huahai Pharmaceutical Co Liabilities
- Zhejiang Huahai Pharmaceutical Co Equity
- Zhejiang Huahai Pharmaceutical Co AAQS
- Zhejiang Huahai Pharmaceutical Co Employees
- Zhejiang Huahai Pharmaceutical Co ROE
- Zhejiang Huahai Pharmaceutical Co ROA
- Zhejiang Huahai Pharmaceutical Co ROCE